Literature DB >> 499309

Distribution of elimination of hydroflumethiazide in man.

O Brørs, S Jacobsen.   

Abstract

The pharmacokinetics of hydroflumethiazide (HFT) were investigated after intravenous and oral administration to healthy subjects. After intravenous infusion, HFT behaved according to a three-compartment model. Two distribution phases were observed, with mean half-lives of 0.26 and 0.85 h, reflecting distribution to red blood cells and tissues. Mean biological half-life (t 1/2 beta) after infusion was 5.2 h. Renal blood and plasma clearance of HFT, as well as the ratio renal blood clearance/renal plasma clearance of HFT, were lower after infusion than during the infusion, due to the distribution characteristics of HFT. After a single oral dose of 2 micronmol/kg, t 1/2 beta was significantly shorter in all subjects than after a single oral dose of 6 micronmol/kg, with mean t 1/2 beta of 8.7 and 17.9 h, respectively. Due to lack of a sufficiently sensitive method for determination of HFT in plasma, it could not be established whether the observed dose-dependent difference in biological half-life of HFT was caused by variation in renal clearance and/or the volume of distribution.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 499309     DOI: 10.1007/bf00563119

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Quantitative fluorometric TLC procedure for determination of hydroflumethiazide in biological fluids,.

Authors:  Y Garceau; I Davis; J Hasegawa
Journal:  J Pharm Sci       Date:  1974-11       Impact factor: 3.534

3.  General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics.

Authors:  L Z Benet
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

4.  Absorption kinetics of hydroflumethiazide.

Authors:  P J McNamara; W A Colburn; M Gibaldi
Journal:  J Clin Pharmacol       Date:  1978-04       Impact factor: 3.126

5.  Pharmacokinetics of a single oral dose of hydroflumethiazide in health and in cardiac failure.-.

Authors:  O Brørs; S Jacobsen; E Arnesen
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

6.  Pharmacokinetics of hydroflumethiazide during repeated oral administration to healthy subjects.

Authors:  O Brørs; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

7.  Pharmacokinetics of orally administered hydroflumethiazide in man.

Authors:  G J Yakatan; R B Smith; E L Frome; J T Doluisio
Journal:  J Clin Pharmacol       Date:  1977-01       Impact factor: 3.126

8.  Fluorometric determination of hydroflumethiazide in human plasma and urine after its oral administration.

Authors:  O Brors; S Jacobsen; E Arnesen
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

9.  Excretion of hydroflumethiazide in bile and urine of man.

Authors:  O Brørs; J F Haffner; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.